$PLYX

Polaryx Therapeutics, Inc. (PLYX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0002075320 0002075320 2026-07-19 2026-07-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor

SciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.

Yang Alex Keun Mo (Chief Executive Officer) purchased 88,453 indirectly-held shares of Polaryx Therapeutics, Inc. (PLYX) at $4.07 ($0.36M total) on 2026-05-27.

Polaryx Therapeutics said it completed a PIPE financing of 2,502,696 shares at an average ~$4 per share, with no SEC registration statement for resale. The company plans to use $10 million gross proceeds plus existing cash to start its Phase 2 SOTERIA basket trial for PLX-200 across four LSDs, extending runway to Q2 2027. Shares were up 8.76% to $2.73.